PULSE NEWS WIRE
Clear, Actionable Intelligence
17,800+
Articles
4,436
Companies
2,300+
Exclusive to PNW
<2 min
To English

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from Convano Inc. was processed by Pulse News Wire on March 27, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Convano Subsidiary Signs Contract for Botulinum Toxin Approval

TOKYO, Mar 27 (Pulse News Wire) – Convano Inc. (6574.T) announced its subsidiary, Synksh Healthcare Co., Ltd., signed a contract with CM Plus to seek PMDA approval for botulinum toxin products in Japa

View all Convano Inc. disclosures →

Share this disclosure: Share on X Share on LinkedIn